You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Foundayo ™ (orforglipron) tablet
0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Foundayo™ (orforglipron) be used in combination with other weight loss medications?
Use of orforglipron with other weight loss drugs has not been studied. Concomitant use with another glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.
See important safety information, including boxed warning, in the attached prescribing information.
Use of Weight Loss Medications
Orforglipron is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor.1
Concomitant use with another GLP-1 receptor agonist is not recommended.1
The use of orforglipron in combination with other weight loss medications has not been studied in the weight management clinical trials.
Participants were excluded from participating in the orforglipron weight management clinical trials if they had used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 180 days prior to screening.2,3
Furthermore, medications intended to promote weight loss, including prescribed, over the counter, or alternative remedies were prohibited throughout the study.2,4
Enclosed Prescribing Information
FOUNDAYO™ (orforglipron) tablets, for oral use, Lilly
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
- Foundayo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
- Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. https://doi.org/10.1056/NEJMoa2511774
- Horn DB, Ryan DH, Giljanovic Kis S, et al; ATTAIN-2 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025;406(10522):2927-2944. https://doi.org/10.1016/S0140-6736(25)02165-8.
- Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: April 01, 2026